Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Axitinib toxicity

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

Adverse event (%) Standard dose Titration
Grade 1–2
87.3%
Grade 3
12.7%
Grade 4
0%
Grade 1–2
86.6%
Grade 3
13.4%
Grade 4
0%
Haematologic 9.5 0.7 11.4 2
Hypertension 20.9 5.4 25.7 5.7
Gastro-intestinal 32.4 4.1 34.3
Hypothyroidism 17.6 0.7 25.7
Stomatitis/mucositis 8.1 8.5
Fatigue 43.2 7.4 48.6 8.6
Hepatic 2.8 2 2.9 5.7
Hand-foot syndrome 12.2 2 17.2 2.9
Dysphonia 11.5 0.7 11.4 2.9